Wordt geladen...
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
BACKGROUND: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to disease characteristics, prescription through a d...
Bewaard in:
| Gepubliceerd in: | Respir Res |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094468/ https://ncbi.nlm.nih.gov/pubmed/33947414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01714-y |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|